Global leishmaniasis surveillance: 2021, assessing the impact of the COVID-19 pandemic

Ruiz-Postigo, J.A.; et al. World Health Organization WHO (2022) C_WHO
Surveillance mondiale de la leishmaniose: 2021, évaluation de l’impact de la pandémie de COVID-19 The aims of this report are to update the results of the GHO leishmaniasis indicators reported by Member States to WHO up to 2021, to describe specific indicators of gender and age distribution, relapses, the AmBisome® donation programme, selected outbreaks, case fatality rates for visceral leishmaniasis (VL, also known as kala-azar), rates of co-infection with HIV and VL and the burden of post-kala-azar dermal leishmaniasis (PKDL). This report also describes the Kala-azar Elimination Programme in South-East Asia and adverse events after administration of antileishmanial drugs.